Levetiracetam Studied for Potential Role in Alzheimer’s Prevention

Recent scientific studies have examined levetiracetam, a medication used for epilepsy, for its possible impact on Alzheimer’s disease processes.

Researchers have observed that levetiracetam alters the way amyloid precursor protein (APP) is processed in neurons, leading to reduced formation of amyloid-beta 42 plaques in both cell and animal models. The drug’s action involves binding to the SV2A protein, which slows synaptic vesicle recycling and keeps APP on the cell surface longer, resulting in less conversion to amyloid-beta 42.

Levetiracetam has been approved for seizure management for several decades and is currently being evaluated in Alzheimer’s research, particularly for its effect on reducing hippocampal hyperactivity. Analysis of clinical data from the National Alzheimer’s Coordinating Center indicated that individuals with Alzheimer’s disease who were taking levetiracetam lived modestly longer after diagnosis compared to those on other anti-epileptic drugs or none.

Researchers have stated that the drug’s possible preventive effect would require administration well before the onset of dementia symptoms, potentially many years in advance. They have also indicated that levetiracetam would not be effective once dementia has developed.

What the numbers show

• Levetiracetam has been approved for seizure treatment since the 1990s
• Studies found reduced amyloid-beta 42 plaque production in cell and animal models
• Clinical data showed modestly longer survival for Alzheimer’s patients taking levetiracetam

The mechanism identified by researchers suggests that levetiracetam’s effect on APP processing is linked to its interaction with SV2A, a protein involved in synaptic function. By slowing the recycling of synaptic vesicles, the drug keeps APP on the cell surface for a longer period, which reduces its internal breakdown into amyloid-beta 42.

Current research is also exploring levetiracetam’s impact on hippocampal hyperactivity, a feature observed in Alzheimer’s disease. This line of investigation is part of broader efforts to identify potential preventive strategies for neurodegenerative conditions.

Levetiracetam’s established use as an anticonvulsant provides a foundation for its ongoing evaluation in Alzheimer’s disease studies. Researchers continue to assess its effects in various experimental and clinical settings to determine its potential role in prevention or disease modification.

Further studies are needed to clarify the timing, dosage, and population groups that might benefit from levetiracetam in the context of Alzheimer’s disease, according to the research findings currently available.

* This article is based on publicly available information at the time of writing.